scholarly journals Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma

Cancer ◽  
2003 ◽  
Vol 97 (7) ◽  
pp. 1663-1671 ◽  
Author(s):  
Bradley C. Leibovich ◽  
Michael L. Blute ◽  
John C. Cheville ◽  
Christine M. Lohse ◽  
Igor Frank ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals PD12-03 ASSOCIATION OF PARTIAL AND RADICAL NEPHRECTOMY ON SURVIVAL IN YOUNG PATIENTS WITH NON-CLEAR CELL RENAL CELL CARCINOMA

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Kristian Stensland ◽  
Jared Schober ◽  
David Canes ◽  
Navneet Ramesh ◽  
Brendan Waldoch ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Young Patients ◽  
Cell Renal Cell Carcinoma

scholarly journals MP36-05 CHANGES IN PATTERN OF RECURRENCE OVER TIME AFTER RADICAL NEPHRECTOMY IN PATIENTS WITH LOCALIZED CLEAR CELL RENAL CELL CARCINOMA

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Kenji Tanabe ◽  
Kazutaka Saito ◽  
Kazuaki Nakagomi ◽  
Chizuru Arisawa ◽  
Tetsuro Tsukamoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Over Time ◽  
Pattern Of Recurrence

scholarly journals 1095: Association of Abnormal Preoperative Laboratory Values with Survival Following Radical Nephrectomy for Clinically Confined Clear Cell Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 352-352
Author(s):  
James S. Magera ◽  
Bradley C. Leibovich ◽  
Christine M. Lohse ◽  
Shomik Sengupta ◽  
John C. Cheville ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Laboratory Values

scholarly journals Comparative effectiveness of adrenal sparing radical nephrectomy and non-adrenal sparing radical nephrectomy in clear cell renal cell carcinoma: Observational study of survival outcomes

2015 ◽  
Vol 9 (9-10) ◽  
pp. 583 ◽  
Author(s):  
Gregory J. Nason ◽  
Leon G. Walsh ◽  
Ciaran E. Redmond ◽  
Niall P. Kelly ◽  
Barry B. McGuire ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Observational Study ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clear Cell ◽  
Risk Groups ◽  
Survival Outcomes ◽  
Cell Renal Cell Carcinoma

Introduction: We compare the survival outcomes of patients with clear cell renal cell carcinoma (RCC) treated with adrenal sparing radical nephrectomy (ASRN) and non-adrenal sparing radical nephrectomy (NASRN).Methods: We conducted an observational study based on a composite patient population from two university teaching hospitals who underwent RN for RCC between January 2000 and December 2012. Only patients with pathologically confirmed RCC were included. We excluded patients undergoing cytoreductive nephrectomy, with loco-regional lymph node involvement. In total, 579 patients (ASRN = 380 and NASRN = 199) met our study criteria. Patients were categorized by risk groups (all stage, early stage and locally advanced RCC). Overall survival (OS) and cancer-specific survival (CSS) were analyzed for risk groups. Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazards regression.Results: The median follow-up was 41 months (range: 12–157). There were significant benefits in OS (ASRN 79.5% vs. NASRN 63.3%; p = 0.001) and CSS (84.3% vs.74.9%; p = 0.001), with any differences favouring ASRN in all stage. On multivariate analysis, there was a trend towards worse OS (hazard ratio [HR] 1.759, 95% confidence interval [CI] 0.943–2.309, p = 0.089) and CSS (HR 1.797, 95% CI 0.967–3.337, p = 0.064) in patients with NASRN (although not statistically significant). Of these patients, only 11 (1.9%) had adrenal involvement.Conclusions: The inherent limitations in our study include the impracticality of conducting a prospective randomized trial in this scenario. Our observational study with a 13-year follow-up suggests ASRN leads to better survival than NASRN. ASRN should be considered the gold standard in treating patients with RCC, unless it is contraindicated.

Sign in / Sign up

Export Citation Format

Share Document